RICHMOND, Va., Oct 24, 2007 (BUSINESS WIRE) -- Insmed Inc. (Nasdaq:INSM) today announced that it will release its 2007 third quarter results after market closes on Thursday, November 8, 2007.
Management will host an investment community conference call beginning at 4:30 p.m. (ET) on Thursday, November 8, 2007 to discuss the financial results, provide a business update and answer questions.
Individuals interested in listening to the live conference call may do so by dialing 877-407-0778 toll free within the U.S. and Canada, or 201-689-8565 for international callers.
A telephone replay will be available approximately two hours after the call for two weeks by dialing 877-660-6853 from the U.S., or 201-612-7415 for international callers. The account # is 286 and conference id # 259108.
Individuals interested in listening to the conference call via the Internet may do so by visiting www.insmed.com. A replay will be available on the Company's Web site for 90 days.
About Insmed Incorporated
Insmed is a biopharmaceutical company focused on the development of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit www.insmed.com.
Forward Looking Statements
This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow on biologics market may be unsuccessful, our common stock could be delisted from the Nasdaq Global Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.